Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study
- 1.1k Downloads
Thromboembolism and bleeding after mechanical heart valve replacement are still unsolved problems, particularly for patients requiring anticoagulative bridging therapy. The aim of this study was to investigate whether rivaroxaban, a new oral selective and direct coagulation factor Xa inhibitor, is as effective as enoxaparin and unfractionated heparin (UFH) in preventing thrombus formation on mechanical heart valves using an in vitro system. Blood from healthy male donors was anticoagulated with either UFH, enoxaparin, rivaroxaban at 300 ng/ml, (n = 10 each), or rivaroxaban at 30 ng/ml (n = 3). Mechanical aortic valve prostheses were placed into the in vitro testing system THIA II and exposed to the anticoagulant blood mixtures at a pulsatile flow for 60 min. Overall thrombus weight, coagulation parameters, and electron microscopic features of thrombus formation on the valve surface were quantified as endpoints. The mean thrombus weights were 163 ± 64 mg for group 1 (UFH), 341 ± 63 mg for the group 2 (enoxaparin), 238 ± 83 mg for group 3 (rivaroxaban 300 ng/ml) and 1.739 ± 16 mg for group 4 (rivaroxaban 30 ng/ml). Whereas high-dosed rivaroxaban showed no significant differences compared to UFH or enoxaparin, low-dosed rivaroxaban generated a massive thrombus generation, thus differing significantly from all other treatment groups regarding the thrombus weight. We hypothesize that high-dose rivaroxaban is a competitive oral available alternative to UFH and LMWH’s, that might be a worthwhile alternative for patients in need of anticoagulative bridging therapy. Prospective studies have to evaluate if rivaroxaban might even overcome the limitations of OAC in patients after implantation of artificial heart valves.
KeywordsAnticoagulation Rivaroxaban Mechanical heart valves Thrombosis
This study was funded by an unrestricted grant from BAYER-Schering® Pharma.
Conflicts of interest
Mrs. Elisabeth Perzborn is an employee of Bayer HealthCare®.
- 2.Cortelazzo S, Finazzi G, Viero P, Galli M, Remuzzi A, Parenzan L, Barbui T (1993) Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Heamost 69:316–320Google Scholar
- 5.Palareti G, Leali N, Poggi SCM, Manotti C, D’Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 348:423–428PubMedCrossRefGoogle Scholar
- 7.Bonow RO, Carabello BA, Chatterjee K, de Leon ACJR, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O’Gara PT, O’Rourke RA, Otto CM, Shah PM, Shanewise JS, American College of Cardiology/American Heart Association Task Force on Practice Guidelines (2008) 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease) Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 52(13):1–142CrossRefGoogle Scholar
- 8.Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L, Wenink A, Task force on the management of valvular hearth disease of the European Society of Cardiology; ESC committee for practice guidelines (2007) Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 28(2):230–268PubMedCrossRefGoogle Scholar
- 14.Spyropoulos AC, Turpie AG, Dunn AS, Kaatz S, Douketis J, Jacobson A, Petersen H, REGIMEN Investigators (2008) Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry). Am J Cardiol 102(7):883–889PubMedCrossRefGoogle Scholar
- 15.Schlitt A, Hamilton K, Maegdefessel L, Dahm M, Theis C, Eichler M, Brockmann O, Steinseifer U, Hauroeder B, Hitzler WE, Rupprecht HJ (2006) Comparison of fondaparinux, low molecular-weight heparin and unfractionated heparin in preventing thrombus formation on mechanical heart valves: results of an in vitro study. J Heart Valve Dis 15(6):809–814PubMedGoogle Scholar
- 16.Maegdefessel L, Linde T, Michel T, Hamilton K, Steinseifer U, Friedrich I, Schubert S, Hauroeder B, Raaz U, Buerke M, Werdan K, Schlitt A (2009) Argatroban and bivalirudin compared to unfractionated heparin in preventing thrombus formation on mechanical heart valves Results of an in vitro study. Thromb Haemost 101(6):1163–1169PubMedGoogle Scholar
- 17.Maegdefessel L, Linde T, Krapiec F, Hamilton K, Steinseifer U, van Ryn J, Raaz U, Buerke M, Werdan K, Schlitt A (2010) In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves. Thromb Res 126(3):e196–e200PubMedCrossRefGoogle Scholar
- 18.Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kälebo P, Muelhofer E, Misselwitz F, Eriksson BI (2008) Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 100(3):453–461PubMedGoogle Scholar
- 25.Kubitza D, Becka M, Voith B (2005) Effect of enoxaparin on the safety, tolerability, pharmacodynamics and pharmacokinetics of BAY 59–7939–an oral, direct Factor Xa inhibitor. J Thromb Haemost 3(Suppl 1):P1704Google Scholar
- 27.Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2006) No interaction between the novel, oral direct Factor Xa inhibitor BAY 59–7939 and digoxin. J Clin Pharmacol 46: 702 (Abstract 11)Google Scholar
- 29.Kubitza D, Becka M, Mueck W, Zuehlsdorf M (2006) The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban—an oral, direct Factor Xa inhibitor. Blood 108: Abstract 905Google Scholar
- 31.Halabi A, Kubitza D, Zuehlsdorf M, Becka M, Mueck W, Maatouk H (2007) Effect of hepatic impairment on the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban—an oral, direct Factor Xa inhibitor. J Thromb Haemost 5(Suppl 2): Abstract P-M-635Google Scholar
- 34.Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S, RECORD2 Investigators (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372(9632):31–39PubMedCrossRefGoogle Scholar
- 36.Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD, RECORD4 investigators (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373(9676):1673–1680PubMedCrossRefGoogle Scholar
- 37.Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, ATLAS ACS-TIMI Gibson CM 46 study group (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374(9683):29–38PubMedCrossRefGoogle Scholar
- 38.Becker R, Berkowitz SD, Breithardt G, Califf RM, Fox K, Hacke W, Halperin J, Hankey G, Mahaffey K, Nessel C, Singer D, Ardissino D, Avezum A, Aylward P, Biedermann B, Breithardt G, Bode C, Carolei A, Corbalán R, Csiba L (2010) Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 159(3):340–347CrossRefGoogle Scholar